Peptilogics
PrivateLast Round
Series B
Extension
Oct 16, 2025
Est. Valuation
$420M
Total Funding Raised
$135.67M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Peptilogics operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Series B Extension round in October 2025.
Peptilogics is a biotechnology company that develops novel peptide therapeutics using an AI-powered drug discovery platform to treat multidrug-resistant bacterial infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Peptilogics Comparables
Compare Peptilogics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Osteal Therapeutics | 83% | |
| Trellis Bioscience | 80% | |
| Omnix Medical Ltd. | 79% |
For institutional investors. Book with your work email.
Peptilogics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Oct 16, 2025 | ||||
| Grant | Jan 9, 2025 | ||||
| Series B | Dec 21, 2020 | ||||
| Grant | Feb 25, 2020 | ||||
| Series A | Sep 29, 2017 | ||||
Seed | Oct 21, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Peptilogics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pittsburgh Life Sciences Greenhouse | Seed |
| Narya Capital | Series B Extension |
| AMR Action Fund | Series B Extension |
| BlueTree Allied Angels | Series A |
| CARB-X | Grant |
| Beyond Ventures | Series B Extension |
| Gaingels | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 69% MoM.
- Aug 9, 2026
Lead candidate PLG0206 in Phase 2/3 trial for prosthetic joint infection.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 18, 2026
Peptilogics is developing zaloganan as a broad-spectrum anti-biofilm drug for device-related infections, with prosthetic joint infection as its initial indication and potential use alongside surgery.
- hiresAug 18, 2026
Peptilogics appoints veteran orthopedic executive Tim Czartoski to its board of directors as it advances zaloganan for prosthetic joint infections and other potential medical device-related infections on Aug 18th '26.
For institutional investors. Book with your work email.
Peptilogics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Peptilogics's valuation, stock price, and market status.
Is Peptilogics a public or private company?
Peptilogics is a private company.
What is the current stock price of Peptilogics?
Peptilogics is a private company, so its shares have no public market price. Caplight tracks Peptilogics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Peptilogics worth (valuation)?
Peptilogics's valuation is estimated at $420.0M based on funding round data.
Can I buy Peptilogics stock?
Peptilogics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Peptilogics's last funding round?
Peptilogics's most recent funding round was Series B Extension on October 16, 2025.
Who are the main investors in Peptilogics?
Key investors in Peptilogics include Founders Fund, Thiel Bio, Presight Capital.
Will Peptilogics IPO soon?
No public IPO plans have been announced for Peptilogics.
How can I track Peptilogics secondary market activity?
Caplight tracks bids, offers, and trades in Peptilogics's shares on secondary markets.